Scandion Oncology Q2 2023: CORIST part 3 data around the corner - Redeye

Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e is the primary catalyst for the company’s share in the coming 12-18 months. Further, we believe CORIST part 3 top-line data in H2 2023e and more granular PANTAX data in Q4 2023e-H1 2024e might provide minor catalysts. We do some housekeeping in our model.

Länk till analysen i sin helhet: https://www.redeye.se/research/937000/scandion-oncology-q2-2023-corist-part-3-data-around-the-corner?utm_source=finwire&utm_medium=RSS